Share on StockTwits

Flamel Technologies S.A. (NASDAQ:FLML) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 368,405 shares, a decrease of 48.8% from the July 31st total of 719,373 shares, ARN reports. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 228,299 shares, the short-interest ratio is currently 1.6 days.

A number of research firms have recently commented on FLML. Analysts at Zacks downgraded shares of Flamel Technologies S.A. from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. They now have a $16.20 price target on the stock. Analysts at Leerink Swann initiated coverage on shares of Flamel Technologies S.A. in a research note on Friday, August 1st. They set an “outperform” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Flamel Technologies S.A. presently has a consensus rating of “Buy” and a consensus target price of $17.90.

Shares of Flamel Technologies S.A. (NASDAQ:FLML) opened at 14.15 on Thursday. Flamel Technologies S.A. has a 52 week low of $5.30 and a 52 week high of $15.96. The stock’s 50-day moving average is $14.29 and its 200-day moving average is $12.64. The company’s market cap is $545.9 million.

Flamel Technologies S.A. (NASDAQ:FLML) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.05. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $9.92 million. During the same quarter in the prior year, the company posted ($1.29) earnings per share. On average, analysts predict that Flamel Technologies S.A. will post $-0.28 earnings per share for the current fiscal year.

Flamel Technologies SA has a pipeline of niche specialty pharmaceutical products. The Company’s drug delivery platforms are focused on developing safer, more efficacious formulations of drugs to address unmet medical needs.

Receive News & Ratings for Flamel Technologies SA (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies SA (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.